<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The human guanylate-binding protein 1 (GBP-1) is among the proteins the most highly induced by interferon-γ (IFN-γ) in every cell type investigated as yet </plain></SENT>
<SENT sid="1" pm="."><plain>In vivo, GBP-1 expression is associated with the presence of <z:mp ids='MP_0001845'>inflammation</z:mp> and has been observed in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> (IBD) and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), the expression of GBP-1 in the <z:e sem="disease" ids="C1511789" disease_type="Disease or Syndrome" abbrv="">desmoplastic</z:e> stroma has been previously reported to correlate with the presence of an IFN-γ-dominated T helper type 1 (Th1) micromilieu and with an increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related 5-year survival </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, the analysis of GBP-1 expression in a series of 185 CRCs by immunohistochemistry confirmed that GBP-1 is expressed in stroma cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and revealed a significantly less frequent expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, which was contradictory with the broad inducibility of GBP-1 </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, three of six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines treated with IFN-�� were unable to express GBP-1 indicating that <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> cells tend to downregulate GBP-1 </plain></SENT>
<SENT sid="5" pm="."><plain>On the contrary, non-transformed colon epithelial cells strongly expressed GBP-1 in vitro in presence of IFN-γ and in vivo in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Reconstitution of GBP-1 expression in a negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line inhibited cell proliferation, migration and invasion </plain></SENT>
<SENT sid="7" pm="."><plain>Using <z:chebi fb="40" ids="33697">RNA</z:chebi> interference, we showed that GBP-1 mediates the antitumorigenic effects of IFN-γ in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, GBP-1 was able to inhibit <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>Altogether, these results suggested that GBP-1 acts directly as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and the loss of GBP-1 expression might indicate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> evasion from the IFN-γ-dominated Th1 immune response </plain></SENT>
</text></document>